the role of non-covalent btk inhibitors in the treatment of non-hodgkin lymphoma
Published 6 hours ago • 6 plays • Length 1:00Download video MP4
Download video MP3
Similar videos
-
1:40
updates on the management of hodgkin lymphoma: early-stage disease vs advanced stage disease
-
5:29
developing new prognostic scores in hodgkin lymphoma
-
2:39
new findings and challenges in the use of immunotherapy in hodgkin lymphoma
-
1:18
hodgkin lymphoma highlights at ash 2022 and future outlooks
-
0:55
intracranial disease in hodgkin lymphoma: a case study
-
2:55
the discovery of pathogenic germline variants in patients with myeloma
-
3:17
nodular lymphocyte-predominant hodgkin lymphoma
-
11:42
thalassemia highlights at ash 2023: novel therapies, trial updates & the value of precision medicine
-
4:32
recent advances in the treatment of lr-mds: commands and imerge trial data
-
3:08
welcome to the video journal of hematology & hematological oncology 🎥🩸
-
1:37
the role of ctdna in hodgkin lymphoma
-
1:04
emerging concepts in hodgkin lymphoma
-
0:53
the current state of mrd in hodgkin lymphoma
-
1:24
novel agents for the treatment of hodgkin lymphoma: brentuximab vedotin and nivolumab
-
1:27
diagnosis and risk stratification in hodgkin lymphoma: updates and novel approaches
-
1:25
predictors and outcomes of extramedullary disease in multiple myeloma
-
2:44
data on new therapeutic strategies in hodgkin lymphoma
-
1:27
challenges in understanding the genomic landscape of hodgkin lymphoma
-
1:21
hodgkin lymphoma highlights from ash 2023: nivo-avd versus bv-avd in patients with hl
-
1:26
improving tools and techniques for mrd detection in hodgkin lymphoma
-
1:59
hodgkin lymphoma: prognostic markers in the era of novel treatments